Illumina (ILMN) Given Consensus Recommendation of “Buy” by Brokerages

Illumina (NASDAQ:ILMN) has been given an average recommendation of “Buy” by the twenty-four brokerages that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and fifteen have issued a buy rating on the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $240.81.

A number of brokerages have commented on ILMN. BidaskClub raised Illumina from a “hold” rating to a “buy” rating in a research report on Saturday, March 10th. Deutsche Bank set a $275.00 price target on Illumina and gave the stock a “buy” rating in a research report on Tuesday, January 16th. Cowen lifted their price target on Illumina from $250.00 to $275.00 and gave the stock an “outperform” rating in a research report on Monday, January 22nd. Leerink Swann lifted their price target on Illumina from $250.00 to $276.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 31st. Finally, Morgan Stanley lifted their price target on Illumina from $145.00 to $157.00 and gave the stock an “underweight” rating in a research report on Wednesday, January 31st.

How to Become a New Pot Stock Millionaire

Shares of ILMN stock traded down $5.76 during mid-day trading on Friday, reaching $235.36. The company had a trading volume of 855,359 shares, compared to its average volume of 729,377. Illumina has a 1 year low of $167.16 and a 1 year high of $256.64. The company has a current ratio of 3.99, a quick ratio of 3.55 and a debt-to-equity ratio of 0.43. The stock has a market cap of $34,597.92, a P/E ratio of 47.45, a price-to-earnings-growth ratio of 3.11 and a beta of 0.93.

Illumina (NASDAQ:ILMN) last announced its earnings results on Tuesday, January 30th. The life sciences company reported $1.44 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.22 by $0.22. Illumina had a return on equity of 21.71% and a net margin of 26.56%. The firm had revenue of $778.00 million for the quarter, compared to the consensus estimate of $752.04 million. During the same period in the previous year, the business earned $0.85 EPS. The firm’s revenue for the quarter was up 25.7% on a year-over-year basis. sell-side analysts predict that Illumina will post 4.59 EPS for the current year.

In other news, Director Robert S. Epstein sold 1,250 shares of the business’s stock in a transaction dated Friday, December 29th. The stock was sold at an average price of $217.38, for a total value of $271,725.00. Following the completion of the transaction, the director now owns 8,838 shares of the company’s stock, valued at approximately $1,921,204.44. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director A Blaine Bowman sold 3,000 shares of the business’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $230.82, for a total value of $692,460.00. Following the completion of the transaction, the director now directly owns 19,868 shares of the company’s stock, valued at approximately $4,585,931.76. The disclosure for this sale can be found here. In the last three months, insiders sold 53,137 shares of company stock valued at $12,263,490. Insiders own 0.89% of the company’s stock.

Several hedge funds have recently modified their holdings of ILMN. Hemenway Trust Co LLC raised its holdings in Illumina by 0.6% in the 4th quarter. Hemenway Trust Co LLC now owns 37,895 shares of the life sciences company’s stock worth $8,280,000 after purchasing an additional 227 shares during the period. Daiwa Securities Group Inc. raised its holdings in Illumina by 4.3% in the 4th quarter. Daiwa Securities Group Inc. now owns 5,543 shares of the life sciences company’s stock worth $1,211,000 after purchasing an additional 229 shares during the period. Private Asset Management Inc. raised its holdings in Illumina by 2.2% in the 4th quarter. Private Asset Management Inc. now owns 11,072 shares of the life sciences company’s stock worth $2,419,000 after purchasing an additional 240 shares during the period. Fairfield Bush & CO. raised its holdings in Illumina by 1.4% in the 4th quarter. Fairfield Bush & CO. now owns 18,985 shares of the life sciences company’s stock worth $4,148,000 after purchasing an additional 255 shares during the period. Finally, Nordea Investment Management AB raised its holdings in Illumina by 4.1% in the 3rd quarter. Nordea Investment Management AB now owns 7,076 shares of the life sciences company’s stock worth $1,410,000 after purchasing an additional 278 shares during the period. 91.40% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “Illumina (ILMN) Given Consensus Recommendation of “Buy” by Brokerages” was first reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3300590/illumina-ilmn-given-consensus-recommendation-of-buy-by-brokerages.html.

About Illumina

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.

Analyst Recommendations for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Contrasting Brunswick  and Électricité de France
Contrasting Brunswick and Électricité de France
Head to Head Review: Sensata Technologies  vs. Its Competitors
Head to Head Review: Sensata Technologies vs. Its Competitors
Head-To-Head Comparison: Great Western Bancorp  vs. HopFed Bancorp
Head-To-Head Comparison: Great Western Bancorp vs. HopFed Bancorp
Zacks: Brokerages Anticipate Simpson Manufacturing  Will Announce Quarterly Sales of $238.34 Million
Zacks: Brokerages Anticipate Simpson Manufacturing Will Announce Quarterly Sales of $238.34 Million
Positive News Coverage Somewhat Unlikely to Impact Liberty Expedia  Stock Price
Positive News Coverage Somewhat Unlikely to Impact Liberty Expedia Stock Price
Hibbett Sports  Rating Lowered to Hold at ValuEngine
Hibbett Sports Rating Lowered to Hold at ValuEngine


© 2006-2018 Ticker Report. Google+.